-- Clinical Trial and Clinical Pharmacology Data Support Upcoming Enrollment of Omeros’ Zaltenibart Phase 3 Clinical Program in PNH -- Morag Griffin, MBChB, FRCPath, Consultant in Haematology of St.
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback